Weekly topotecan is well tolerated in the third-line or later treatment of patients with epithelial ovarian carcinoma (EOC) and may prolong time to disease progression No significant financial ...
Efficacy and safety findings from a phase II study of capecitabine (X) as first-line therapy in Japanese patients (pts) with advanced/metastatic colorectal cancer (MCRC) No significant financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results